Blinatumomab

SAN DIEGO — In this video, Marlise R. Luskin, MD, MSCE, highlights updates from two groups evaluating blinatumomab and ponatinib for the treatment of acute lymphoblastic leukemia.

SAN DIEGO — In this video, Marlise R. Luskin, MD, MSCE, discusses results from a phase 3 randomized trial that investigated the addition of blinatumomab to standard chemotherapy for pediatric B-cell acute lymphoblastic leukemia.

In this video, Daniel DeAngelo, MD, PhD, discusses the results of a study presented at ASH Annual Meeting that examined the addition of blinatumomab to standard chemotherapy for pediatric B-cell acute lymphoblastic leukemia.

SAN DIEGO — The addition of blinatumomab to chemotherapy extended DFS for children with newly diagnosed B-cell acute lymphoblastic leukemia, according to results of a randomized phase 3 trial presented at ASH Annual Meeting and Exposition.

Healio spoke with John Molina, MD, MEd, about research updates on the use of immunotherapy in leukemia from this year’s Society of Hematologic Oncology Annual Meeting.

Use of blinatumomab with consolidation chemotherapy significantly extended OS for adults with minimal residual disease-negative B-cell precursor acute lymphoblastic leukemia, according to randomized phase 3 study results.

More than 20% of reported cases of adverse events following bispecific T-cell engager therapies involved a cardiovascular event, findings reported in Journal for ImmunoTherapy of Cancer showed.

Patients with post-transplant relapsed B-cell acute lymphoblastic leukemia who received chimeric antigen receptor T-cell therapy had superior outcomes compared with alternative approaches, study results showed.

The FDA announced several regulatory actions the past few weeks.

The addition of blinatumomab to Interfant-06 chemotherapy appeared safe for infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia, according to data published in The New England Journal of Medicine.